alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 576–600 of 904 studies (page 24 of 37) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 904 studies tagged small — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of neuroscience research 2016-06-27

There is significant evidence that pathways involving inflammation and oxidative-nitrosative stress (ONS) play a key pathophysiological role in promoting cognitive dysfunction. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

High Systolic Blood Pressure Induces Cerebral Microvascular Endothelial Dysfunction, Neurovascular Unit Damage, and Cognitive Decline in Mice

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Hypertension (Dallas, Tex. : 1979) 2019-01-01

A chronic and gradual increase in pulse pressure (PP) is associated with cognitive decline and dementia in older individuals, but the mechanisms remain ill-defined. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of neuropathology and experimental neurology 2003-12-01

Sporadic, late-onset Alzheimer disease (AD) constitutes the most frequent cause of dementia in the elderly population. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

White matter damage is associated with matrix metalloproteinases in vascular dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Stroke 2001-05-01

Vascular disease causes multi-infarct dementia (MID) or Binswanger's disease (BD), the latter of which is a progressive form of vascular dementia (VaD) associated pathologically with fibrinoid and hyaline changes in brain arterioles with injury to the white matter. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Neighborhood‐Level Disadvantage with Cerebrovascular Disease Neuropathology in a National Sample of Brain Donors

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-12-01

We found that ∼25% of donors lived in high deprivation contexts, 52% had at least one incidence of CVD, and the cohort identified as .05). 3 key findings →

Participants: 7,187 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer-related individual factors modulate effects of transcranial direct current stimulation strength on white matter integrity in mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Scientific Reports 2025-12-17

Transcranial direct current stimulation (tDCS) is a promising non-invasive intervention for mild cognitive impairment (MCI). 4 key findings →

Design: longitudinal study Participants: 55 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Retinal microvascular alterations reflect cerebral small vessel disease burden in frontotemporal dementia: a multimodal OCTA–MRI Study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s Research & Therapy 2025-12-23

FTD patients demonstrated significantly reduced retinal and choriocapillaris perfusion compared to CU (all p < 0.001). 5 key findings →

Design: cross-sectional Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enlarged perivascular spaces correlate with blood-brain barrier leakage and cognitive impairment in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-02-09

BackgroundThe clinical significance of enlarged perivascular spaces (EPVS) in Alzheimer' s disease (AD) was ambiguous. 2 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of small vessel disease progression with longitudinal cognitive decline across mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-01-10

In the CN group, cerebral microbleed (CMB) progression was associated with the decline in language function (p < 0.05), and deep white matter hyperintensity (WMH) progression was associated with a decline in memory function (p < 0.05). 4 key findings →

Design: longitudinal study Participants: 432 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neuroinflammation and blood–brain barrier dysfunction in cerebral small vessel disease: mechanisms, biomarkers, and therapeutic implications

✓ Peer-reviewed alzhub usefulness score 45 out of 100. European journal of medical research 2026-01-23

Cerebral small vessel disease (CSVD) is a chronic, progressive cerebrovascular disorder affecting small arteries, arterioles, venules, and capillaries, and is a leading contributor to stroke, vascular dementia, and cognitive impairment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive training reorganizes lateralization of fronto-parietal network in vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain Communications 2025-01-01

These findings suggest that subcortical VCIND modifies the relationship between FPN lateralization and cognitive functions, rather than altering the lateralization pattern itself. 1 key finding →

Participants: 30 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Silent yet impaired: Hidden memory processing deficits in asymptomatic individuals with moderate‐to‐severe white matter hyperintensities

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2026-01-01

Individuals with msWMH showed systematic deficits in face-memory processing across encoding, maintenance, and retrieval, accompanied by reduced theta power and synchronization, altered alpha power, and disrupted theta-gamma coupling. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Community Socioeconomic Disadvantage relates to White Matter Hyperintensity Burden in Mid-to-Late Life Adults

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Biopsychosocial science and medicine 2025-07-17

Residing in communities characterized by socioeconomic disadvantage may confer risk for neurodegenerative brain changes and future neuropathology. 1 key finding →

Participants: 388 Evidence: low

Full summary, score breakdown and related studies → Original source

Lower plasma vitamin E levels are associated with the frailty syndrome: the InCHIANTI study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2006-03-01

Our findings show an association between low circulating levels of one of the most important components of the human antioxidant system and the presence of frailty. 3 key findings →

Participants: 827 Evidence: low

Full summary, score breakdown and related studies → Original source

From across this tag

9 of the 903 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed